Treats inflammatory and pruritic manifestations of moderate to severe…. ANDA 206075, held by Novel Labs Inc. Clobetasol Propionate.
As of Nov 16, 2026, ANDA 206075 (Clobetasol Propionate), held by Novel Labs Inc, was first approved by FDA on Nov 23, 2015, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Clobetasol propionate topical solution, USP is indicated for short-term topical treatment of inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp. Treatment beyond 2 consecutive weeks is not recommended, and the total dosage should not exceed 50 mL/week because of the potential for the drug to suppress the HPA axis. This product is not recommended for use in pediatric patients under 12 years of age.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 23, 2015 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Clobetasol Propionate0.05% · solution;topical | Clobetasol Propionate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters